$CBLL

Taylor Joseph Michael sold $101K of CBLL

Taylor Joseph Michael sold 5,500 shares of Ceribell, Inc. (CBLL) at $18.41 ($0.10M total) on 2026-06-11.

Original reporting
SEC EDGAR · Taylor Joseph Michael
Published Jun 15, 2026, 5:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 5:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CBLL
Neutral
medium confidence
Mentioned
$CBLL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

Insider selling can modestly affect sentiment, but without new operational/financial information it typically does not drive sustained repricing.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is unlikely to be a standalone catalyst.

03

What to watch

The article notes 'Pre-arranged 10b5-1 plan: No,' which can increase interpretive sensitivity, but the disclosure still lacks any stated reason or follow-on company event.

Relevance 4/10Novelty 5/10Timing: post-filing disclosure on 2026-06-15 for a 2026-06-11 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Ceribell, Inc.

Company-level read

Ticker impact

$CBLLNeutralMedium confidence
Context

Ceribell director Taylor Joseph Michael filed an open-market sale of 5,500 shares at $18.41 on 2026-06-11.

Expected impact

Likely limited near-term impact; treat as a mild sentiment headwind rather than a catalyst.

Evidence & confidence

The filing is primary-source but describes a single director’s sale without accompanying company-specific fundamentals, guidance, or enforcement action.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Director sales can be pre-planned for liquidity/taxes and may not reflect bearish fundamentals, especially with large remaining holdings.

Key entities

  • Ceribell, Inc.

    Company whose director filed an open-market sale of shares via SEC Form 4.

  • Taylor Joseph Michael

    Director who sold 5,500 shares at $18.41 on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

$CBLLMedAI 8/10

Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis

Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.

$CBLLHigh

Ceribell Reports Second Quarter 2026 Financial Results

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor